Drug profile · INN
brolucizumab
BEOVU
brolucizumab (BEOVU) is a vascular endothelial growth factor a inhibitor. Associated with Novartis Pharmaceuticals.
EMA: approved TGA: approved Sensory organs (S01) S01
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — brolucizumab
- Class
- Sensory organs (S01)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
brolucizumab (BEOVU) is a vascular endothelial growth factor a inhibitor. Associated with Novartis Pharmaceuticals.
Key facts
INN brolucizumab
Brand BEOVU
Mechanism Vascular endothelial growth factor A inhibitor
Target Vascular endothelial growth factor A, long form
Therapeutic class Sensory organs (S01)
ATC code S01
Originator Novartis Pharmaceuticals
Mechanism of action
Vascular endothelial growth factor A inhibitor
Primary target: Vascular endothelial growth factor A, long form
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is brolucizumab?
brolucizumab (BEOVU) is a vascular endothelial growth factor a inhibitor. Associated with Novartis Pharmaceuticals.
What is the brand name for brolucizumab?
BEOVU is a marketed brand name for brolucizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.